Format

Send to

Choose Destination
J Cyst Fibros. 2017 Jul;16(4):525-527. doi: 10.1016/j.jcf.2017.05.008. Epub 2017 Jun 8.

Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.

Author information

1
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, United States. Electronic address: cameron.mckinzie@unchealth.unc.edu.
2
Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
3
Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
4
Department of Psychiatry and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States.

Abstract

In both phase III studies of LUM/IVA, as well as an extension study, worsening of mental health was not reported as a common side effect. Here we describe five cases in adolescent female patients that suggest a worsening of anxiety or depression associated with its use. In these five patients, two experienced suicidal ideation and three made suicide attempts that resulted in psychiatric hospitalizations.

KEYWORDS:

CFTR modulator; Cystic fibrosis

PMID:
28602538
DOI:
10.1016/j.jcf.2017.05.008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center